ABSTRACT
Myelin basic protein [MBP] is one of the most important constituents of the CNS myelin sheaths. It is supposed that an autoimmune response directed against MBP is crucial in the demyelination process in patients with multiple sclerosis. Studies have proved that free anti-MBP level in CSF of MS patients is declined when the patient entered into clinical remission. Some researchers evaluate the changes in serum or CSF level of this antibody during immunomodulatory therapy; the results are different and the relation between the changes in this antibody and response to treatment is poorly investigated
The objective of this study was to assess the relation between the changes in serum level of anti-MBP and clinical remission in patients during treatment with fingolimod. 37 MS patients that were non responder to interferon and glatiramer acetate and were candidates to receive fingolimod were nominated for this study. In this study, the serum level of anti-MBP was evaluated before and after 3 and 6 months of therapy and clinical remission was assessed by changes in Expanded Disability Status Scale [EDSS] scores
The result of this study showed that MS patients, after treatment with interferon, have lower serum anti-MBP level than healthy control group and this difference is statistically significant [p =0.03]
The present study demonstrated that the serum anti-MBP level in MS patient during 6 months of treatment with fingolimod significantly decreased [p<0.001]. However, there was no significant difference in EDSS of MS patients during 6 months of treatment with fingolimod [p < 0.001]
ABSTRACT
Polycystic ovary syndrome [PCOS] is a common endocrine / metabolic disorder in women of reproductive age .Abdominal adiposity and obesity are frequently present in PCOS. It now appears that, obesity is associated with a low-grade inflammation of white adipose tissue. Adipokines play a significant role in the pathogenesis of a low-grade inflammation associated with obesity. Among variety of adipokines, resistin and visfatin are proposed as important pro inflammatory mediators and they have recently been suggested to be associated with obesity related diseases. The aim of this study is to evaluate the correlation of visfatin and resistin serum levels and the ratio of these two adipokines with BMI in PCOS women under age of 35 years old. Twenty eight young women with clinically confirmed PCOS disease [14 lean and 14 obese], and 12 young, healthy and lean women with stable weight and BMI<25 were enrolled. Blood was obtained from the included persons, and visfatin and resistin were assessed by ELISA method. We did not observe any significant differences in serum visfatin and resistin concentrations and also in the Visfatin/Resistin ratio between PCOS and control group. Also we did not found a significant correlation between visfatin and resistin with BMI. This study demonstrated that serum resistin and visfatin levels do not seem to be directly involved in the pathology of PCOS
ABSTRACT
GranymeH is a functional cytotoxic serine protease of NK cell granules,which expands the cell death-inducing repertoire of innate immune system.The purpose of this study was to determine GranymeH[GZMH]level in breast cancer[BC] and healty women.This study was performed on 30 patients with BC and 30 healty woman.GZMH and Estrogen levels were measured in cancer patients and healty women subsequently using ELISA and Radioimmunoassay[RIA] methods. Mean GZMH value was lower in BC than healty women[p<0.0001] and mean Estrogen level was higher in BC patients in comparison to healty women [p<0.003].Our finding indicates probability of existance of suppressor or a problem in production of GZMH in cancer patients
ABSTRACT
Perforin[p] is the primary mediator of short term cytotoxicity, it is accumulated in response to proinflammatory cytokines and stored in T lymphocyte, NK cells and NKT cells are released upon activation. Perforin is a prototypical cytotoxic molecule involved in cell mediated immunity against various pathogens, alloantigens and particularly different tumors.The purpose of this study was to determine perforin level in prostate cancer [P.Ca] and Benign Prostatic Hyperplasia [BPH] This is study was performed on 59 patients consisting of 28 patients with P.Ca and 31 patients with BPH.Perforin and PSA levels were measured in cancer and BPH patients using ELISA method. Mean Perforin value was significantly lower in P.Ca patients than in BPH patients [p < 0.01] where as mean serum PSA level was significantly higher in the cancer patients in comparison to the BPH group [P < 0.01 Our finding indicate probability of problem in expression of cytotoxic molecule ,perforin in and around the tumor